Novo Integrated Sciences is a small Canadian multidisciplinary healthcare company that delivers non-physician primary care services — physiotherapy, chiropractic care, occupational therapy, and massage therapy — through 14 corporate-owned clinics and a contracted affiliate clinic network, primarily in Ontario. Novo's clinicians treat orthopedic, musculoskeletal, sports injury, and neurological conditions. A significant portion of the business serves elderly patients: Novo contracts with long-term care homes, retirement homes, and community-based home care programs to provide physiotherapy and occupational therapy, largely funded by the Ontario Ministry of Long-Term Care. The core business model is fee-for-service, with revenue driven by clinic count, patient volume, and payer mix across private insurers, government programs, and out-of-pocket patients. About 90% of clinicians are independent contractors, giving Novo a variable cost structure. Beyond its core services, Novo is developing a telehealth and remote patient monitoring platform (Novo Connect), a nutraceutical and supplement product business (through Acenzia, PRO-DIP, and Terragenx), and plans for U.S. expansion via micro-clinics in fitness retail locations — though all three remain early-stage. Novo has historically grown through stock-funded acquisitions, but its November 2024 Nasdaq delisting, with shares now trading on the OTC Pink market, limits its ability to use equity as acquisition currency going forward.